<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979105</url>
  </required_header>
  <id_info>
    <org_study_id>UdeA1005</org_study_id>
    <nct_id>NCT03979105</nct_id>
  </id_info>
  <brief_title>Cardiovascular Safety After Continuous Ketamine Infusion</brief_title>
  <official_title>Cardiovascular and Neuropsychiatric Side Effects in Ketamine Analgesic Infusions in Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study that evaluate the cardiovascular and neuropsychiatric side effects of
      ketamine analgesic infusions for acute pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute pain and opioid tolerance is an important symptom in patients after surgery.

      Ketamine in analgesic infusion has been described to decrease acute pain, in patients with
      opioid tolerance. Ketamine use has been associated with side effects, which are doses
      dependant. Those side effects are mainly cardiovascular: Hypertension, tachycardia, and
      neuropsychiatric: delirium, hallucinations,nightmares that potentially compromise recovery of
      patients.

      Objective:

      To determine retrospectively in data bases the frequency of tachycardia, hypertension,
      delirium, hallucinations and nightmares, in adult patients that received ketamine infusions
      before and after administration of this drug in the first 48 hours to treat acute and
      postoperative pain
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tachycardia</measure>
    <time_frame>2 days</time_frame>
    <description>Presence of absence of tachycardia (100 or above beats for minute) as physiological parameter recorded with cardioscope in the first 48 hours in clinical chart database after the infusion of ketamine has started.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypertension</measure>
    <time_frame>2 days</time_frame>
    <description>Presence or absence of hypertension (140/90 mm Hg or above ) as physiological parameter recorded with electronic arm manometer in the first 48 hours in clinical chart database after the infusion of ketamine has started.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>2 days</time_frame>
    <description>Presence of absence of delirium reported in clinical records electronic database by nurse or physician in the first 48 hours after the infusion of ketamine has started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hallucinations</measure>
    <time_frame>2 days</time_frame>
    <description>Presence of absence hallucinations reported in clinical electronic database records by nurse or physician in the first 48 hours after the infusion of ketamine has started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nightmares</measure>
    <time_frame>2 days</time_frame>
    <description>Presence of absence of nightmares reported in clinical electronic database records by nurse or physician, in the first 48 hours after the infusion of ketamine has started.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Pain</condition>
  <condition>Ketamine Adverse Reaction</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine infusion</arm_group_label>
    <description>Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison</description>
    <arm_group_label>Ketamine infusion</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with acute pain after surgery or medical painful condition
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years old

          -  Acute and Postoperative pain

          -  Ketamine infusion at 0.15 mg/kg/h or below

        Exclusion Criteria:

          -  Cognitive disfunction psychiatric illness

          -  Acute cardiovascular disease

          -  Anemia with Hb less than 7 g/dl

          -  Decompensated hyperthyroidism

          -  Low cardiac output

          -  Incomplete medical history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana M Cadavid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>hospital universitario San Vicente Fundacion</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adriana Cadavid, MD</name>
      <address>
        <city>Medellín</city>
        <state>Antiquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Avidan MS, Fritz BA, Maybrier HR, Muench MR, Escallier KE, Chen Y, Ben Abdallah A, Veselis RA, Hudetz JA, Pagel PS, Noh G, Pryor K, Kaiser H, Arya VK, Pong R, Jacobsohn E, Grocott HP, Choi S, Downey RJ, Inouye SK, Mashour GA. The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: protocol for an international multicentre randomised controlled trial. BMJ Open. 2014 Sep 17;4(9):e005651. doi: 10.1136/bmjopen-2014-005651.</citation>
    <PMID>25231491</PMID>
  </reference>
  <reference>
    <citation>Kase D, Imoto K. The Role of HCN Channels on Membrane Excitability in the Nervous System. J Signal Transduct. 2012;2012:619747. doi: 10.1155/2012/619747. Epub 2012 Aug 13.</citation>
    <PMID>22934165</PMID>
  </reference>
  <reference>
    <citation>Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine Infusions for Treatment Refractory Headache. Headache. 2017 Feb;57(2):276-282. doi: 10.1111/head.13013. Epub 2016 Dec 27.</citation>
    <PMID>28025837</PMID>
  </reference>
  <reference>
    <citation>Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009 Oct;145(3):304-11. doi: 10.1016/j.pain.2009.06.023. Epub 2009 Jul 14.</citation>
    <PMID>19604642</PMID>
  </reference>
  <reference>
    <citation>Radvansky BM, Shah K, Parikh A, Sifonios AN, Le V, Eloy JD. Role of ketamine in acute postoperative pain management: a narrative review. Biomed Res Int. 2015;2015:749837. doi: 10.1155/2015/749837. Epub 2015 Oct 1. Review.</citation>
    <PMID>26495312</PMID>
  </reference>
  <reference>
    <citation>Garg N, Panda NB, Gandhi KA, Bhagat H, Batra YK, Grover VK, Chhabra R. Comparison of Small Dose Ketamine and Dexmedetomidine Infusion for Postoperative Analgesia in Spine Surgery--A Prospective Randomized Double-blind Placebo Controlled Study. J Neurosurg Anesthesiol. 2016 Jan;28(1):27-31. doi: 10.1097/ANA.0000000000000193.</citation>
    <PMID>26018671</PMID>
  </reference>
  <reference>
    <citation>Assouline B, Tramèr MR, Kreienbühl L, Elia N. Benefit and harm of adding ketamine to an opioid in a patient-controlled analgesia device for the control of postoperative pain: systematic review and meta-analyses of randomized controlled trials with trial sequential analyses. Pain. 2016 Dec;157(12):2854-2864. Review.</citation>
    <PMID>27780181</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

